Vascular Biogenics (NASDAQ:VBLT) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Thursday.
According to Zacks, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. “
Several other analysts have also issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Vascular Biogenics in a research report on Tuesday, November 7th. Chardan Capital lifted their target price on shares of Vascular Biogenics from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, November 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Vascular Biogenics currently has a consensus rating of “Hold” and an average target price of $15.67.
Vascular Biogenics (NASDAQ:VBLT) traded down $0.60 during mid-day trading on Thursday, reaching $6.55. 374,090 shares of the company traded hands, compared to its average volume of 245,642. The firm has a market capitalization of $214.02, a price-to-earnings ratio of -8.23 and a beta of -3.00. Vascular Biogenics has a 52 week low of $3.90 and a 52 week high of $9.05.
Vascular Biogenics (NASDAQ:VBLT) last announced its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.04). analysts predict that Vascular Biogenics will post -0.9 EPS for the current fiscal year.
A hedge fund recently bought a new stake in Vascular Biogenics stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Vascular Biogenics Ltd (NASDAQ:VBLT) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 22,100 shares of the biopharmaceutical company’s stock, valued at approximately $135,000. Zurcher Kantonalbank Zurich Cantonalbank owned 0.08% of Vascular Biogenics as of its most recent SEC filing. Institutional investors own 6.59% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Vascular Biogenics (VBLT) Upgraded by Zacks Investment Research to Hold” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/01/vascular-biogenics-vblt-upgraded-by-zacks-investment-research-to-hold.html.
About Vascular Biogenics
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.